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Abstract
Background: Preterm birth is in quantity and in severity the most important topic in obstetric care in the
developed world. Progestogens and cervical pessaries have been studied as potential preventive treatments with
conflicting results. So far, no study has compared both treatments.
Methods/design: The Quadruple P study aims to compare the efficacy of vaginal progesterone and cervical
pessary in the prevention of adverse perinatal outcome associated with preterm birth in asymptomatic women
with a short cervix, in singleton and multiple pregnancies separately. It is a nationwide open-label multicentre
randomized clinical trial (RCT) with a superiority design and will be accompanied by an economic analysis.
Pregnant women undergoing the routine anomaly scan will be offered cervical length measurement between 18
and 22 weeks in a singleton and at 16–22 weeks in a multiple pregnancy. Women with a short cervix, defined as
less than, or equal to 35 mm in a singleton and less than 38 mm in a multiple pregnancy, will be invited to
participate in the study.
Eligible women will be randomly allocated to receive either progesterone or a cervical pessary. Following
randomization, the silicone cervical pessary will be placed during vaginal examination or 200 mg progesterone
capsules will be daily self-administered vaginally. Both interventions will be continued until 36 weeks gestation or
until delivery, whichever comes first.
Primary outcome will be composite adverse perinatal outcome of perinatal mortality and perinatal morbidity
including bronchopulmonary dysplasia, intraventricular haemorrhage grade III and IV, periventricular leukomalacia
higher than grade I, necrotizing enterocolitis higher than stage I, Retinopathy of prematurity (ROP) or culture
proven sepsis. These outcomes will be measured up until 10 weeks after the expected due date. Secondary
outcomes will be, among others, time to delivery, preterm birth rate before 28, 32, 34 and 37 weeks, admission to
neonatal intensive care unit, maternal morbidity, maternal admission days for threatened preterm labour and costs.
(Continued on next page)
* Correspondence: m.d.vanzijl@amc.nl
1Department of Obstetrics and Gynaecology, Academic Medical Center
(AMC), Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
van Zijl et al. BMC Pregnancy and Childbirth  (2017) 17:284 
DOI 10.1186/s12884-017-1454-x
(Continued from previous page)
Discussion: This trial will provide evidence on whether vaginal progesterone or a cervical pessary is more effective
in decreasing adverse perinatal outcome in both singletons and multiples.
Trial registration: Trial registration number: NTR 4414. Date of registration January 29th 2014.
Keywords: Preterm birth, Singletons, Multiples, Prevention, Pessary, Progesterone
Background
Preterm birth (PTB) is defined as delivery before 37
completed weeks of gestation. PTB affects over 12,000
pregnancies per year in the Netherlands [1] and is the
most important cause of perinatal mortality and morbid-
ity, and subsequent neurodevelopmental sequelae. Simi-
larly, neonatal morbidity is strongly increased in case of
preterm birth. A follow up study among a cohort of
Dutch children born prior to 32 weeks showed that the
prevalence of a severe handicap among surviving children
was 10% [2].
In women with a singleton pregnancy, the spontan-
eous preterm birth rate in The Netherlands is around
5%. It results in a perinatal mortality rate in 0.8% and a
severe disability rate in 0.7%, while 2% of the children
suffer from moderate disability [3]. Women with a
multiple pregnancy have a much higher risk of preterm
delivery. The incidence of preterm delivery in women
with a twin pregnancy is almost 50%, with 1.8, 7 and
14% delivering before 28, 32 and 34 weeks of gestation
respectively. As a consequence, women with a twin
pregnancy have an 8% perinatal mortality, 7% severely
disabled children and 20% moderately disabled children
[4]. It is known that a short cervix, bacterial vaginosis,
bacteriuria and maternal factors such as maternal
periodontal disease, low socio-economic status, smoking
and both high and low maternal BMI increase risk of
preterm birth [5].
Until a decade ago, there were no effective interven-
tions for the prevention of preterm birth in low-risk
pregnancies. However, in the last decade two potentially
important breakthroughs have been established: proges-
terone and pessary. In 2014, an updated Cochrane
systematic review reported on the effectiveness of pro-
gesterone in the prevention of preterm birth (RR 0.62,
95% CI 0.39–0.98) in women with threatened or estab-
lished preterm labour, the author’s concluded that due
to the low number of included trials, there was insufficient
evidence to justify progestational agents as a tocolytic
agent for women presenting with preterm labour [6].
However a recent meta-analysis of individual patient
data indicated that in asymptomatic women with
singleton or multiple pregnancies and a short cervix,
progesterone generated lower rates of preterm delivery
(26% vs. 36%; OR 0.45, 95% CI 0.25–0.80) and lower
rates of perinatal mortality, although this difference did
not reach statistical significance (15% vs. 17%; OR 0.69,
95% CI 0.38–1.3) [7].
An individual patient data meta-analysis on 13 trials
(7536 children) in multiple pregnancies using progesto-
gens (intramuscular 17-hydroxyprogesterone caproate
(17Pc) or vaginal progesterone) showed no overall effect
of progestogens on adverse perinatal outcome in twin
pregnancies (RR 1.1; 95% CI 0.97–1.4 for 17Pc and RR
0.97; 95% CI 0.77–1.2 for vaginal progesterone) [8].
Nevertheless, vaginal progesterone showed a reduction
in adverse perinatal outcome among women with a
cervical length equal or below 25 mm (RR 0.57; 95% CI
0.47–0.70 and RR 0.56; 95% CI 0.42–0.75, respectively).
The recently published OPPTIMUM trial showed no
statistically significant impact on the reduction of spon-
taneous PTB < 34 weeks or fetal death (OR 0.69; 95% CI
0.39–1.20) or composite adverse neonatal outcome (OR
0.54; 95% CI 0.25–1.16) in the asymptomatic short
cervix subgroup. However neonatal death occurred less
frequent in the progesterone group (OR 0.17; 95% CI
0.06–0.49). Furthermore, no harm of progesterone was
detected when cognitive scores at 2 years of age were
compared (−0.48; 95% CI -2.77-1.81) [9].
A second potential breakthrough in the prevention
of preterm birth is the use of a cervical pessary [10].
The PECEP trial [11] showed that a cervical pessary
reduced preterm birth before 34 weeks in women
with a singleton pregnancy and short cervical length
(<25 mm) (6% versus 27%). The composite neonatal
morbidity did not differ between both groups (RR
0.64; 95% CI 0.27–1.5). Two other RCT’s by Hui
et al. and Nicolaides et al. couldn’t reproduce these
results. Nicolaides et al. randomized 935 women with
a singleton pregnancy to either a cervical pessary or ex-
pectant management. The authors found no difference in
preterm birth rates before 34 weeks (OR 1.12; 95% CI
0.75–1.69) [12]. The mean gestational age at randomisa-
tion was higher in this trial (GA 23 + 5) compared to the
trial by Goya et al. (GA 22 + 3) and this might have influ-
enced the effect of the pessary. Within the smaller, prema-
turely ended, Chinese trial (n = 108) birth before 34 weeks
occurred in 9.4% and 5.5% in the pessary and expectant
management group respectively (p = 0.46) [13] Due to
slow recruitment and new published results of the
PECEP-group, the researchers decided to stop recruitment
and report the results of their interim analysis.
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In twin pregnancies several studies assessed the effect of
pessaries. Within the Dutch Consortium for Healthcare
Evaluation and Research in Obstetrics and Gynaecology -
NVOG Consortium 2.0, the ProTwin trial was finished,
which studied the effectiveness of pessary in unselected
twin pregnancies in reducing spontaneous preterm birth
and adverse neonatal outcomes. Although there was no
overall treatment effect of the pessary, the pessary signifi-
cantly reduced preterm delivery rates before 32 weeks in a
subgroup of women with a cervix less than the 25th per-
centile (38 mm) (11% vs. 25%, RR 0.44; 95%CI 0.20–0.98).
More importantly, within this subgroup, adverse perinatal
outcome rate was substantially lower in the pessary group
as compared to no intervention (7% vs. 30%, RR 0.23 95%
CI; 0.09–0.60) [14]. Long-term follow-up of this study is
expected to be published shortly. A more recent trial in
women with a twin gestation and a short cervix by Goya
et al. revealed a significant reduction of spontaneous pre-
term birth <34 weeks in the group that received a cervical
pessary (RR 0.41 (95% CI 0.22–0.76)). No difference in
composite perinatal morbidity and mortality was observed
between the groups [15]. The recent trial, by Nicolaides et
al., in which 1180 women with a twin pregnancy without a
specific cervical length cut-off were allocated to a pessary
or expectant management, found no effect of a cervical
pessary on preterm birth rates <34 weeks (RR 1.05; 95% CI
0.79–1.4) and adverse neonatal outcome (RR 1.09; 95% CI
0.85–1.4) [16]. The subgroup analysis of 214 women with a
cervical length below 25 mm also indicated no differences.
In view of the studies mentioned above, two conclu-
sions can be drawn. First, a short cervix measured at the
beginning of the second trimester identifies women at
risk for preterm birth [17]. Second, both progestogens
and cervical pessary have shown conflicting but promis-
ing results for women who are at increased risk for
preterm birth due to a short cervix. Both interventions
are likely to be introduced in clinical practice since they
are non-invasive and potentially cause a cost-reduction.
Until now, no study has directly compared progester-
one administration with cervical pessary in a random-
ized clinical trial (RCT). Therefore, we propose to
perform an RCT to compare the efficacy of vaginal pro-
gesterone and cervical pessary in the prevention of ad-
verse perinatal outcomes associated with preterm birth
in women with a short cervix. The present project is
needed to guide the choice between both treatments.
Methods/Design
Aims
We will perform a multicenter randomized clinical trial
(Pessary or Progesterone to Prevent Preterm delivery in
women with short cervical length: the Quadruple P trial)
comparing the efficacy of vaginal progesterone capsules
and pessary in the reduction of adverse perinatal outcome.
Participants/eligibility criteria
Women ≥18 years of age with a singleton or multiple
pregnancy (both twin and higher order) undergoing the
routine anomaly scan (18–22 weeks for singleton preg-
nancy and 16–22 weeks for multiple pregnancies) will be
offered cervical length measurement. Subsequently we
will randomize women with a short cervix, defined as
≤35 mm in singletons and <38 mm in multiples, to a
cervical pessary or vaginal progesterone. Both women
who receive antenatal care by midwifery practices and
women who receive care in the hospital can be included.
Exclusion criteria are a previous spontaneous preterm
birth before 34 weeks of gestation, a cervical cerclage in
this pregnancy, participation in the “Quadruple P
study” in a previous pregnancy, identified major con-
genital abnormalities or death of one or both foetuses,
cervical length < 2 mm or cervical dilatation of more
than 3 cm. (see Fig. 1).
Procedures, recruitment and randomization
The study will be performed within the Dutch Consor-
tium for Healthcare Evaluation and Research in
Obstetrics and Gynaecology - NVOG Consortium 2.0,
a collaboration of approximately 70 obstetric practices
(academic and non-academic hospitals) in the Netherlands
(www.studies-obsgyn.nl).
All eligible women will be referred to a participating
hospital for counseling. Good clinical practice (GCP)
trained nurses will counsel patients, ask informed con-
sent, perform randomization and collect data.
Before entry into the study, the investigator or an
authorized member of the investigational staff must ex-
plain to potential subjects the aims, methods, reasonably
anticipated benefits, and potential hazards of the study.
Subjects will be informed that their participation is volun-
tary and that they may withdraw consent to participate at
any time. They will be informed that declining participa-
tion will not affect their care. Subjects may withdraw at
any time or be withdrawn by the investigator if the woman
violates the study plan or for administrative and /or safety
reasons.
Each subject must give written consent. The subject
will be given sufficient time to read the patient informa-
tion and the informed consent form and gets the oppor-
tunity to ask questions. An independent physician will
be accessible regarding any questions the subjects may
have. The consent form must be signed before any
study-related activity can take place. A copy of the
informed consent form must be given to the subject.
Documents are available through the study website.
Patient information is available in Dutch and English
and contains information regarding insurance for
patients participating in the trial.
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Randomization will be centrally controlled using an
on-line computerised randomisation service, once pa-
tient data have been entered in a web-based database.
Centres will be able to access the randomisation service
24 h/day. Subjects will be randomized in a 1:1 ratio to
progesterone or a pessary. Figure 1 Randomization will
be stratified by centre (to prevent any imbalance be-
tween groups in aspects of maternal or neonatal care
that may differ between centres) and by singleton/mul-
tiple pregnancy. Due to the type of interventions, this
study will not be blinded.
Baseline characteristics such as demographic features,
obstetric and medical history will be recorded from all
randomised women in an electronic case report form
(Additional file 1: Appendix 1) in an online database.
This database (OpenClinina) is located at a secure server.
Confidentiality and data security
Initials of subjects and year of birth are recorded in
the electronic database. Each participating hospital re-
ceives a personal login name and password to access
the web-secured database. Linking personal data with
randomisation number can only be done in the clinic
that performed the randomisation. Full access to the
entire database is reserved to some members of the
Fig. 1 Flow diagram Quadruple P study
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research staff, and must be assigned by the trial bureau
and data manager of the NVOG Consortium 2.0.
Intervention
Participants will be allocated to receive either vaginal
progesterone or a cervical pessary (Arabin ®). The cer-
vical pessary will be placed at 18 to 22 weeks in single-
ton pregnancies and at 16 to 22 weeks in multiple
pregnancies, and will stay in situ up to 36 weeks of
gestation or until delivery, whatever comes first. It is in
the patient’s interest that the pessary is placed by an
experienced caregiver to ensure careful placement. In
case of complaints, (vaginal) examination is recommended
to inspect the cervix and reposition or replace the pessary
with another size if necessary. In case of regular contrac-
tions, persistent or recurrent vaginal blood loss or prema-
ture rupture of the membranes, during treatment with a
pessary, the pessary should be removed.
Vaginal progesterone capsules 200 mg will be taken from
time of randomisation onwards up to 36 weeks of gestation
or delivery, whatever comes first. The capsules will be self-
administered vaginally by patients on a daily basis.
The medication will be available at the latest within
five working days after randomization. After delivery
women will return any unused study medication to the
research nurse. The research nurse will count the medi-
cation that is left over, and record this in the case record
from. Medication that is left over will be destroyed by
the pharmacy. The cervical pessary will also be placed
within 5 days after randomization and removed during a
visit to the hospital at 36 weeks of gestation.
Apart from the research intervention subjects will be
treated according to the local protocols in participating
clinics and midwifery practices. In case of a threatening
preterm delivery other interventions can be performed
as usual. Repeating the cervical length measurement is
not routinely advised.
Outcome measures
Primary outcome measure
Primary outcome will be composite adverse perinatal
outcome including both morbidity and mortality, specif-
ically: severe Respiratory Distress Syndrome (RDS),
Bronchopulmonary Dysplasia (BPD), Intraventricular
Haemorrhage grade III and IV (IVH), Periventricular
Leukomalacia (PVL) higher then grade I, Necrotizing
Enterocolitis (NEC) higher then stage I, Retinopathy of
Prematurity (ROP) and culture proven sepsis, patent
ductus arteriosus (PDA), treated seizures, (intrapartum)
stillbirth and death before discharge from the nursery,
all measured up until 10 weeks after the expected due
date. For the specification of the individual components
see Table 1.
Secondary outcome measures
Secondary outcomes will be time between randomisa-
tion and delivery, preterm birth rate before 28, 32, 34
and 37 weeks (spontaneous, iatrogenic and total), birth
weight, (days of ) admission in neonatal intensive care
unit, premature rupture of the membranes (PPROM),
tocolysis (duration), use of corticosteroids, use of magne-
sium sulphate, mode of delivery, Twin Transfusion
Syndrome (TTS), maternal morbidity, maternal admission
Table 1 Specification of outcome measurements
Outcome Defined as
Maternal infections Two measurements of maternal temperature above 37,8 degrees Celsius at a 1 h interval plus a
maternal pulse above 100 beats/min requiring treatment with antibiotics
Maternal side effects Vaginal bleeding, discharge, discomfort and dyspareunia
BPD (severe chronic lung disease) Babies born before 32 weeks: need for >30% oxygen, with or without positive pressure ventilation
or continuous positive pressure at 36 weeks postmenstrual age, or discharge (whichever comes first).
Babies born after 32 weeks: need for >30% oxygen with or without positive pressure ventilation or
continuous positive pressure at 56 days postnatal age, or discharge (whichever comes first).
IVH > grade II Haemorrhage in the germinal matrix, ventricles, or cerebral parenchyma; observed on ultrasound
examination or MRI
PVL > grade I periventricular lucency in the white matter
NEC > stage I The presence of the characteristic clinical features of abdominal distention, with or without rectal bleeding,
and abdominal radiographic finding associated with pneumatosis intestinalis
Early sepsis If prior to or at 72 h of life the infant had an infection marked by positive blood, CSF, or urine (catheterized
or suprapubic) cultures with or without suspicious clinical findings of infection on physical examination.
Late sepsis If after 72 h of life the infant had an infection marked by positive blood, CSF, or urine (catheterized or suprapubic)
cultures with or without suspicious clinical findings of infection on physical examination
OR
If there is clinical evidence of cardiovascular collapse or an unequivocal X-ray confirming infection and often
cardiovascular decomposition
Neonatal meningitis Suspected or proven (caused by any pathogen)
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days for preterm labour. In addition, all components of
the primary outcome will also be assessed separately as a
secondary outcome measure. A cost-effectiveness analysis
will be performed and reported separately from the
primary trial results.
Information on the delivery, maternal and fetal condi-
tion and admission to the hospital of both mother and
child (ren) will be recorded in the electronical case
record form. (Additional file 1: Appendix 1).
Follow-up of women and infants
The outcome measures will be measured until 10 weeks
after expected date of delivery.
The only reason for not obtaining complete informa-
tion is that the patient was lost to follow up or that she
withdrew consent to access her medical chart after
delivery. If a woman refuses to complete her follow-up
visits with the research nurse (RN), the RN will confirm
permission to consult her hospital chart in order to be
able to complete information on the primary outcome of
the study. In this case, her data will be considered in the
final analysis.
At present, no long-term follow-up is planned. How-
ever, if a sufficient budget is awarded the possibilities to
perform a long-term follow-up will be assessed. This will
be added to the trial documents using an amendment.
Permission to approach patients for follow-up research
will be asked via the informed consent.
Statistical issues
Sample size
The study was designed as a superiority trial comparing
the efficacy of vaginal progesterone and pessary in the
prevention of adverse perinatal outcome.
In singleton pregnancies we expect a reduction of ad-
verse perinatal outcome from 5% in the vaginal proges-
terone group to 1% in the pessary group. The proportion
of adverse perinatal outcome of 5% in the vaginal pro-
gesterone is based on the Triple P study [18] which was
performed in a comparable population. The frequency of
adverse perinatal outcome of 1% in the pessary group is
based on the PECEP trial where a 3% poor perinatal out-
come was found [11]. However the PECEP trial included
women with a cervix below 25 mm only. Since we
include women with a cervix below or equal 35 mm, we
expect a lower frequency of adverse perinatal outcome
in our study population. Using a two-sided test with a
type I error of 5% and type II error of 20% and a loss to
follow-up of 10%, we calculated that we would need a
sample size of 628 women (314 per group).
For multiple pregnancies we expected frequencies of
adverse perinatal outcome of 24% per pregnancy in the
vaginal progesterone group and 12% in the pessary
group. In the IPD meta-analysis of Schuit et al. [8]
adverse perinatal outcome was 25% in the progesterone-
group, in a population with a shorter cervix (< 25 mm).
In the ProTwin trial adverse perinatal outcome was 12%
in a comparable population with a similar cervical length
[14]. We expect a 50% reduction of adverse perinatal
outcome in the pessary group. Since multiple gestations
are followed up in the hospital, less patients being lost
to follow up were expected. Using a two-sided test with
a type I error of 5% and type II error of 20% and a loss
to follow-up of 5%, a sample size of 332 women (166 per
group) would be needed to be able to detect a significant
difference.
Data analysis
All analyses will be performed for singleton and multiple
pregnancies separately and will be according to the
intention to treat principle. The primary outcome, that
is adverse perinatal outcome, will be assessed by calcu-
lating and comparing rates in the two groups, using a
random intercept fixed effects binomial model with a
log link function, resulting in a relative risk and 95%
confidence intervals. The random intercept is used to
account for the stratified randomization by centre. In
multiple pregnancies the clustering of children within
one mother will be taken into account in the analysis
using generalised estimating equations instead of a log-
binomial model [19]. Numbers needed to treat will be
calculated when appropriate.
To evaluate the potential of each of the strategies, we
will also perform a per protocol analysis, taking into
account only those cases that were treated according to
protocol.
Secondary study parameter(s)
Time to delivery will be evaluated by Kaplan-Meier esti-
mates, with account for different durations of gestation
at entry, and will be tested with the log rank test. Again,
stratified randomisation will be taken into account by
incorporating centre as a stratification variable. The
other secondary outcome measures will be approached
similarly to the primary outcome measure. Differences
in continuous outcomes between both strategies will also
be assessed using a random intercept fixed effects linear
regression model.
We plan a pre-specified subgroup analysis based on
cervical length (below 25 mm vs. equal to and above
25 mm, and below the 25th percentile vs. between the
25th and 50th percentile vs. above the 50th percentile),
parity (nulliparous vs. multiparous), previous preterm
birth between 34 and 37 weeks (yes vs. no), chorionicity
(monochorionic vs. dichorionic; multiple pregnancies
only), and number of multiples (twins vs. higher order).
Subgroup analysis will be performed by including an
interaction term between the subgrouping variables and
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the treatment allocation (pessary vs. vaginal progesterone).
When the interaction will be found statistically significant
(p < 0.05) we will estimate the treatment effect within the
different strata of the subgroup.
Interim analysis and safety
All AEs will be recorded, either after spontaneous report
by the participant or after observation by the investiga-
tor and his staff. AEs will be followed until they have
abated, or until a stable situation has been reached. De-
pending on the event, follow up may require additional
tests or medical procedures as indicated, and/or referral
to the general physician or a medical specialist.
SAEs need to be reported till end of study, as defined
in the protocol.
SAEs will be reported through the web portal Toetsin-
gOnline to the accredited Medical Ethical Committee
(MEC) that approved the protocol.
An interim analysis for effectiveness will not be per-
formed. In case of a strong positive effect of one of the
investigated interventions, the trial will be continued.
Negative effects will be detected by the data safety moni-
toring committee based on the SAE’s in both treatment
arms.
An interim safety review is planned after all outcomes
are available for 320 patients. Results of these safety
reviews will be reported separately for singleton and
multiple pregnancies. On the basis of these results, the
Data Safety Monitoring Committee (DSMC) can decide
to perform additional safety reviews. Serious events that
may cause concern about the safety of the study (such as
maternal mortality); will be reported to the DSMC
immediately if they occur.
The DSMC can advise to stop the trial at any moment
when the safety of the patients is considered to be in
danger based on the SAE reporting.
Discussion
Prevention of PTB remains one of the main goals in ob-
stetric care. Over the past years both mechanical inter-
ventions such as a cervical pessary and pharmacological
interventions such as progesterone were evaluated.
Vaginal progesterone as well as a pessary have been
shown to be potentially effective measures for the
prevention of preterm birth. Both interventions are rela-
tively simple and can be combined with regular care.
However, up to now, no study has directly compared
treatment with progesterone and cervical pessary.
At this moment, other international study groups have
also set up trials to assess both progesterone and cervical
pessaries as a preventive strategy for preterm birth. Pool-
ing data of these trials can hopefully help to conclude
which intervention is most efficacious in preterm birth
prevention. Ongoing (prospective) individual participant
meta-analysis on progesterone and pessaries (PROMPT)
in singletons and multiples will hopefully give new an-
swers on how to prevent spontaneous preterm deliveries.
Protocols of the different ongoing pessary trials have
committed to use the same outcome variables [20].
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